#BEGIN_DRUGCARD DB02130

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
121-34-6

# ChEBI_ID:
30816

# Chemical_Formula:
C8H7O4

# Chemical_IUPAC_Name:
4-hydroxy-3-methoxybenzoate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A flavoring agent. It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13). [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.43

# Experimental_Logs:
-2.05

# Experimental_Water_Solubility:
1500 mg/L (at 14 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
4-Hydroxy-3-Methoxybenzoate

# HET_ID:
VNL

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C8H8O4/c1-12-7-4-5(8(10)11)2-3-6(7)9/h2-4,9H,1H3,(H,10,11)/p-1

# InChI_Key:
InChIKey=WKOLLVMJNQIZCI-UHFFFAOYSA-M

# Indication:
Not Available

# KEGG_Compound_ID:
C06672

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2130

# Mechanism_Of_Action:
Not Available

# Melting_Point:
211.5 °C

# Molecular_Weight_Avg:
167.1388

# Molecular_Weight_Mono:
167.034433712

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1XLR

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.04

# Predicted_LogS:
-1

# Predicted_Water_Solubility:
1.86e+01 g/l

# Primary_Accession_No:
DB02130

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
23199

# PubChem_Substance_ID:
46509049

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03229

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=CC(=CC=C1O)C([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:49 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
4.51 (at 25 °C)

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X66619

# Drug_Target_1_GenBank_ID_Protein:
43231

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ubiC

# Drug_Target_1_Gene_Sequence:
>498 bp
ATGTCACACCCCGCGTTAACGCAACTGCGTGCGCTGCGCTATTGTAAAGAGATCCCTGCC
CTGGATCCGCAACTGCTCGACTGGCTGTTGCTGGAGGATTCCATGACAAAACGTTTTGAA
CAGCAGGGAAAAACGGTAAGCGTGACGATGATCCGCGAAGGGTTTGTCGAGCAGAATGAA
ATCCCCGAAGAACTGCCGCTGCTGCCGAAAGAGTCTCGTTACTGGTTACGTGAAATTTTG
TTATGTGCCGATGGTGAACCGTGGCTTGCCGGTCGTACCGTCGTTCCTGTGTCAACGTTA
AGCGGGCCGGAGCTGGCGTTACAAAAATTGGGTAAAACGCCGTTAGGACGCTATCTGTTC
ACATCATCGACATTAACCCGGGACTTTATTGAGATAGGCCGTGATGCCGGGCTGTGGGGG
CGACGTTCCCGCCTGCGATTAAGCGGTAAACCGCTGTTGCTAACAGAACTGTTTTTACCG
GCGTCACCGTTGTACTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
1512213	Nishimura K, Nakahigashi K, Inokuchi H: Location of the ubiA gene on the physical map of Escherichia coli. J Bacteriol. 1992 Sep;174(17):5762.
1644192	Siebert M, Bechthold A, Melzer M, May U, Berger U, Schroder G, Schroder J, Severin K, Heide L: Ubiquinone biosynthesis. Cloning of the genes coding for chorismate pyruvate-lyase and 4-hydroxybenzoate octaprenyl transferase from Escherichia coli. FEBS Lett. 1992 Aug 3;307(3):347-50.
1644758	Nichols BP, Green JM: Cloning and sequencing of Escherichia coli ubiC and purification of chorismate lyase. J Bacteriol. 1992 Aug;174(16):5309-16.
8265357	Blattner FR, Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL: Analysis of the Escherichia coli genome. IV. DNA sequence of the region from 89.2 to 92.8 minutes. Nucleic Acids Res. 1993 Nov 25;21(23):5408-17.
8409922	Wu G, Williams HD, Gibson F, Poole RK: Mutants of Escherichia coli affected in respiration: the cloning and nucleotide sequence of ubiA, encoding the membrane-bound p-hydroxybenzoate:octaprenyltransferase. J Gen Microbiol. 1993 Aug;139(8):1795-805.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2741

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
18777

# Drug_Target_1_Name:
Chorismate--pyruvate lyase

# Drug_Target_1_Number_of_Residues:
165

# Drug_Target_1_PDB_ID:
1G1B

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF04345	Chor_lyase

# Drug_Target_1_Protein_Sequence:
>Chorismate--pyruvate lyase
MSHPALTQLRALRYCKEIPALDPQLLDWLLLEDSMTKRFEQQGKTVSVTMIREGFVEQNE
IPEELPLLPKESRYWLREILLCADGEPWLAGRTVVPVSTLSGPELALQKLGKTPLGRYLF
TSSTLTRDFIEIGRDAGLWGRRSRLRLSGKPLLLTELFLPASPLY

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Removes the pyruvyl group from chorismate, with concomitant aromatization of the ring, to provide 4- hydroxybenzoate (4HB) for the ubiquinone pathway

# Drug_Target_1_SwissProt_ID:
P26602

# Drug_Target_1_SwissProt_Name:
UBIC_ECOLI

# Drug_Target_1_Synonyms:
CL
CPL
EC 4.1.3.-

# Drug_Target_1_Theoretical_pI:
8.20

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02130
